Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study.

ABSTRACT:

Background

Target-specific immunotherapies have been shown to effectively treat myasthenia gravis (MG) with less side effects. One such immunotherapy is efgartigimod, a neonatal Fc receptor antagonist, promotes degradation of pathogenic IgG antibodies. However, data specifically focusing on elderly, especially for those over 80 years, remain limited.

Methods

This study included generalized MG patients over 80 years old from four neuromuscular centers who were treated with efgartigimod. Data regarding MG history, treatment regimens, and scores from the MG-ADL, QMG, and MGC scales, as well as adverse events, were prospectively recorded.

Results

Twelve patients with mean age of 82.9 ± 2.5 years were included. Anti-AChR antibodies were positive in 11 patients and anti-MuS

SUBMITTER: Hong Y 

PROVIDER: S-EPMC12631306 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature